NewcelX Ltd. (NCEL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q2
"NewcelX Ltd. remains a pre-commercial biotechnology entity characterized by a total lack of revenue and a history of significant accumulated deficits totaling $74.8M. The company's reliance on external capital to fund R&D and administrative overhead, coupled with a quarterly operating loss of $1.8M, presents an unsustainable financial trajectory. Investors should exercise extreme caution as the current cash position of $1.66M suggests an imminent need for dilutive financing or a strategic transaction to avoid insolvency."
the company's unsustainable burn rate, evidenced by a $1.8M quarterly operating loss against only $1.66M in cash, indicates a high probability of near-term liquidity exhaustion.
NewcelX Ltd. (NCEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Key metrics vs top competitors for NewcelX Ltd. (NCEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.79 | $1.71M | -0.14 | — | — | -140.85% | — | |
| $1.40 | $340.78M | -10.00 | 849.33% | -19.38% | -7.19% | — | |
| $0.83 | $40.16M | -3.19 | -95.28% | -2392.61% | — | — | |
| $0.33 | $21.16M | -0.41 | -28.3% | -82.77% | -92.01% | — | |
| $147.01 | $8.29B | 170.94 | 16.36% | 6.73% | 2.46% | — | |
| $8.00 | $539.15M | -1.27 | -10.08% | -32.82% | -147.1% | — |
NewcelX Ltd. (NCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NCEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NewcelX Ltd. (NCEL) stock FAQ — growth, dividends, profitability & financials explained
NewcelX Ltd. (NCEL) reported a net loss of $4.2M for fiscal year 2024.
NewcelX Ltd. (NCEL) has a return on equity (ROE) of -140.8%. Negative ROE indicates the company is unprofitable.
NewcelX Ltd. (NCEL) had negative free cash flow of $6.3M in fiscal year 2024, likely due to heavy capital investments.